Trial Profile
A Single-arm, Phase II Study of Preoperative Gefitinib for Stage II-IIIa NSCLC With Activating EGFR Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Feb 2021 Status changed from recruiting to completed as per the results published in the Journal of Thoracic and Cardiovascular Surgery.
- 01 Feb 2021 Results assessing efficacy and safety of preoperative gefitinib in patients with stage II-IIIA operable non-small cell lung cancer,published in the Journal of Thoracic and Cardiovascular Surgery
- 07 Jun 2016 Results (n=31) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology